As the pace from DNA to IND continues to accelerate, the timeframe for generating toxicology data is becoming increasingly compressed, making timely material delivery more critical than ever. To meet this challenge, innovative approaches are needed to streamline the supply of tox material essential for these studies, which play a key role in supporting IND submissions. Accelerating the delivery of toxicology materials not only helps reduce development timelines, but also enables drug candidates to reach the clinic faster.
In this webinar, our experts will highlight key strategies and technologies that support faster toxicology material delivery. We’ll introduce new solutions developed by Lonza that can reduce tox material generation time by up to 50%, providing tox material for mAbs and bispecifics in as little as 2.5 months post-transfection and helping to avoid delays in IND submissions. With traditional timelines for tox studies ranging from 4 to 5 months, starting earlier can help mitigate potential bottlenecks and keep development programs on track.
- Maximize speed: Discover our newly developed timelines that can reduce the time to deliver toxicology materials by up to 50%, giving you a head start on your IND submission.
- Ensure compliance: Confidently navigate the regulatory requirements for non-clinical material used in toxicology and IND-enabling studies.
- Enabling Technologies and Streamlined Analytics: Discover lean solutions and technologies that accelerate your material delivery process, along with efficient, robust analytical workflows for toxicology material characterization and release.
- Integrated drug substance/drug product offer: Applying this rapid toxicology material supply approach in rapid clinical timelines is achievable with this new integrated offering.